anti-PARAINFLUENZA VIRUS 3 antibody product blog
Tags: Antibody; Monoclonal Antibody; PARAINFLUENZA VIRUS 3; anti-PARAINFLUENZA VIRUS 3 antibody;
The PARAINFLUENZA VIRUS 3 n/a (Catalog #MBS211451) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s PARAINFLUENZA VIRUS 3 can be used in a range of immunoassay formats including, but not limited to, Immunohistology Frozen, ELISA (EIA), Immunofluorescence (IF).Immunohistology - Frozen: Minimum Dilution: 1/10; Maximum Dilution: 1/50;
ELISA: Minimum Dilution: 1/20; Maximum Dilution: 1/200;
Immunofluorescence: Minimum Dilution: 1/10; Maximum Dilution: 1/50. Researchers should empirically determine the suitability of the PARAINFLUENZA VIRUS 3 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
MBS211451 recognizes haemagglutinin from parainfluenza virus type 3 (HPIV-3), an enveloped single-stranded RNA virus of the Paramyxoviridae family. Parainfluenza viruses are genetically and antigenically divided into the four types HPIV1-4, with HPIV-1, -2 and -3 being major causative agents of lower respiratory infections in the young and immunologically vulnerable.
Perservative Stabilisers: 0.09% Sodium Azide (NaN3)
Preparation: Purified IgG prepared by affinity chromatography on Protein A. Immunogen: Crude viral lysate, native
Buffer Solution: Phosphate buffered saline
Target Species: Viral. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PARAINFLUENZA VIRUS 3 are readily searchable from our website. Different antibodies against the same target such as PARAINFLUENZA VIRUS 3 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.